dm+d
96195007
Medicine Compliance Aid Stability
genericAurobindo Pharma - Milpharm Ltd
Aurobindo Pharma - Milpharm Ltd
generic
Tablets 25mg, 50mg, 100mg, 200mg,
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
20 December 2022
LamictalGlaxoSmithKline UK
GlaxoSmithKline UK
Lamictal
Tablets dispersible 2mg, 5mg, 25mg, 100mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Unsuitable for MCA as dispersible tablets.
20 December 2022
genericMylan
Mylan
generic
Tablets dispersible 25mg, 100mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Unsuitable for MCA as dispersible tablets.
20 December 2022
LamictalGlaxoSmithKline UK
GlaxoSmithKline UK
Lamictal
Tablets 25mg, 50mg, 100mg, 200mg,
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special requrements for storage
18 October 2022
Lactation Safety Information
For epilepsy
For epilepsy
Suitable alternative antiepileptic
Significant published evidence of use in breastfeeding
Significant amounts in breast milk
Long half-life increases risk of accumulation in breastfed infants
Mild thrombocytosis reported in some infants. Single case reports of severe apnoea, reversible anaemia and neutropenia in breastfed infants possibly associated with lamotrigine
Monitor infant for rash, apnoea, drowsiness and poor feeding. If rash occurs breastfeeding should be withheld until the cause can be established.
9 January 2020